Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Non-Current Liabilities (2016 - 2025)

Fennec Pharmaceuticals filings provide 14 years of Total Non-Current Liabilities readings, the most recent being $24.6 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 44.05% to $24.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.6 million, a 44.05% decrease, with the full-year FY2025 number at $24.6 million, down 44.05% from a year prior.
  • Total Non-Current Liabilities hit $24.6 million in Q4 2025 for Fennec Pharmaceuticals, down from $43.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $56.8 million in Q2 2024 to a low of $4.0 million in Q2 2022.
  • Median Total Non-Current Liabilities over the past 5 years was $25.4 million (2023), compared with a mean of $29.0 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 536.24% in 2023 and later tumbled 44.05% in 2025.
  • Fennec Pharmaceuticals' Total Non-Current Liabilities stood at $5.0 million in 2021, then surged by 399.18% to $24.9 million in 2022, then increased by 24.23% to $30.9 million in 2023, then surged by 41.92% to $43.9 million in 2024, then tumbled by 44.05% to $24.6 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $24.6 million (Q4 2025), $43.9 million (Q3 2025), and $43.9 million (Q2 2025) per Business Quant data.